Irish biotech company Elan jumped 5.5 per cent to €21.94 after Goldman Sachs added the Irish biotech company to its “conviction buy” list.
Goldman upgraded the price target on Elan’s American Depositary Receipts from $34.20 to $45.
Shares nudge higher in Europe
By Rachel Morarjee
Published: June 23 2008 11:06 | Last updated: June 23 2008 19:35
You have viewed your allowance of free articles. If you wish to view more, click the button below.
